ES2721478T3 - Nueva variante del factor VIII antihemofílico que tiene actividad específica aumentada - Google Patents
Nueva variante del factor VIII antihemofílico que tiene actividad específica aumentada Download PDFInfo
- Publication number
- ES2721478T3 ES2721478T3 ES11838863T ES11838863T ES2721478T3 ES 2721478 T3 ES2721478 T3 ES 2721478T3 ES 11838863 T ES11838863 T ES 11838863T ES 11838863 T ES11838863 T ES 11838863T ES 2721478 T3 ES2721478 T3 ES 2721478T3
- Authority
- ES
- Spain
- Prior art keywords
- factor viii
- specific activity
- increased specific
- new variant
- antihemophilic factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960000301 factor viii Drugs 0.000 title abstract 5
- 102100026735 Coagulation factor VIII Human genes 0.000 title 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 102000001690 Factor VIII Human genes 0.000 abstract 4
- 108010054218 Factor VIII Proteins 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41043710P | 2010-11-05 | 2010-11-05 | |
| PCT/US2011/059297 WO2012061689A2 (en) | 2010-11-05 | 2011-11-04 | A new variant of antihemophilic factor viii having increased specific activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2721478T3 true ES2721478T3 (es) | 2019-07-31 |
Family
ID=46025129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11838863T Active ES2721478T3 (es) | 2010-11-05 | 2011-11-04 | Nueva variante del factor VIII antihemofílico que tiene actividad específica aumentada |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9150637B2 (enExample) |
| EP (1) | EP2635297B1 (enExample) |
| JP (1) | JP5922141B2 (enExample) |
| KR (1) | KR101948337B1 (enExample) |
| CN (1) | CN103298483B (enExample) |
| AU (1) | AU2011323236B2 (enExample) |
| BR (1) | BR112013011041B1 (enExample) |
| CA (1) | CA2816575C (enExample) |
| CO (1) | CO6720990A2 (enExample) |
| DK (1) | DK2635297T3 (enExample) |
| EA (1) | EA035447B1 (enExample) |
| ES (1) | ES2721478T3 (enExample) |
| IL (1) | IL226158B (enExample) |
| MX (2) | MX347503B (enExample) |
| MY (1) | MY165089A (enExample) |
| SG (2) | SG10201509149VA (enExample) |
| WO (1) | WO2012061689A2 (enExample) |
| ZA (1) | ZA201303816B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2819123T3 (es) | 2015-01-30 | 2021-04-15 | Univ Emory | Proteínas del factor VIII que tienen secuencias ancestrales, vectores de expresión, y usos relacionados con ellos |
| KR102219859B1 (ko) | 2016-06-24 | 2021-02-25 | 재단법인 목암생명과학연구소 | 재조합 단쇄 fviii 및 그 화학 접합물 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4348384A (en) | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| EP0182448A3 (en) | 1984-08-24 | 1987-10-28 | Genetics Institute, Inc. | Production of factor viii and related products |
| MX9203440A (es) | 1985-04-12 | 1992-07-01 | Genetics Inst | Proteinas procoagulantes novedosas. |
| JPS6281327A (ja) | 1985-10-04 | 1987-04-14 | Green Cross Corp:The | 人トロンビン製剤の加熱処理方法 |
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体 |
| JPS6485927A (en) | 1987-09-29 | 1989-03-30 | Green Cross Corp | Hepatitis b vaccine |
| US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| JPH0626980Y2 (ja) | 1987-11-26 | 1994-07-20 | ソニー株式会社 | 誤消去防止機構 |
| WO1989009784A1 (en) | 1988-04-08 | 1989-10-19 | Commonwealth Serum Laboratories Commission | Production of heat-stable factor viii concentrate |
| DK162233C (da) | 1989-11-09 | 1992-03-16 | Novo Nordisk As | Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii |
| IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| US5384132A (en) | 1990-03-20 | 1995-01-24 | Akzo N.V. | Stabilized gonadotropin containing preparations |
| DE4111393A1 (de) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
| US5744446A (en) | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US6180371B1 (en) * | 1996-06-26 | 2001-01-30 | Emory University | Modified factor VIII |
| US5663060A (en) | 1992-04-07 | 1997-09-02 | Emory University | Hybrid human/animal factor VIII |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5888974A (en) | 1992-04-07 | 1999-03-30 | Emory University | Hybrid human/animal factor VIII |
| ATE198277T1 (de) | 1992-10-02 | 2001-01-15 | Genetics Inst | Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| SE9301581D0 (sv) | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
| WO1994029471A1 (en) * | 1993-06-10 | 1994-12-22 | Genetic Therapy, Inc. | Adenoviral vectors for treatment of hemophilia |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| IL113010A0 (en) | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| ZA955642B (en) | 1994-07-07 | 1997-05-06 | Ortho Pharma Corp | Lyophilized imaging agent formulation |
| JPH0899999A (ja) | 1994-09-30 | 1996-04-16 | Chemo Sero Therapeut Res Inst | α１プロテアーゼインヒビターの製造方法 |
| US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| WO1997003191A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| PT1754718E (pt) * | 1996-04-24 | 2011-07-13 | Univ Michigan | Factor viii resistente à inactivação |
| US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| JP2002517180A (ja) | 1997-12-05 | 2002-06-18 | ジ・イミユーン・リスポンス・コーポレーシヨン | 増大された発現を示す新規ベクターおよび遺伝子 |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| US6759216B1 (en) | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
| EP1820516B1 (en) | 1999-02-22 | 2013-07-24 | University of Connecticut | Novel albumin-free factor VIII formulations |
| EP1194161B1 (en) | 1999-07-13 | 2005-11-23 | Biovitrum Ab | Stable factor viii compositions |
| US6333192B1 (en) | 1999-08-09 | 2001-12-25 | North Carolina State University | Method of producing an undifferentiated avian cell culture using avian primordial germ cells |
| US6586574B1 (en) | 1999-08-17 | 2003-07-01 | Nn A/S | Stabilization of freeze-dried cake |
| US7576182B1 (en) | 1999-08-31 | 2009-08-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| PL206105B1 (pl) | 2000-09-19 | 2010-07-30 | Emory Universityemory University | Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej |
| DE60230456D1 (de) * | 2001-10-05 | 2009-01-29 | Expression Therapeutics Llc | Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren |
| US20040249134A1 (en) | 2001-11-30 | 2004-12-09 | Lollar John S. | Factor viii c2 domain variants |
| GB0207092D0 (en) | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
| US7041635B2 (en) * | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| US20050123997A1 (en) | 2003-10-30 | 2005-06-09 | Lollar John S. | Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes |
| US7939634B2 (en) * | 2004-01-27 | 2011-05-10 | Compugen Ltd. | Polynucleotides encoding polypeptides and methods using same |
| PL1750733T3 (pl) | 2004-05-03 | 2014-05-30 | Univ Emory | Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B |
| DK2371856T3 (en) * | 2004-11-12 | 2022-08-08 | Bayer Healthcare Llc | Site-directed modifikation af FVIII |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| WO2009075772A1 (en) | 2007-12-06 | 2009-06-18 | Wyeth | Crystal structure of human factor viii and uses thereof |
-
2011
- 2011-11-04 BR BR112013011041-4A patent/BR112013011041B1/pt active IP Right Grant
- 2011-11-04 MX MX2013005047A patent/MX347503B/es active IP Right Grant
- 2011-11-04 CN CN201180063748.0A patent/CN103298483B/zh active Active
- 2011-11-04 EA EA201390654A patent/EA035447B1/ru not_active IP Right Cessation
- 2011-11-04 EP EP11838863.6A patent/EP2635297B1/en active Active
- 2011-11-04 SG SG10201509149VA patent/SG10201509149VA/en unknown
- 2011-11-04 US US13/883,244 patent/US9150637B2/en active Active
- 2011-11-04 SG SG2013034137A patent/SG190136A1/en unknown
- 2011-11-04 JP JP2013537859A patent/JP5922141B2/ja not_active Expired - Fee Related
- 2011-11-04 WO PCT/US2011/059297 patent/WO2012061689A2/en not_active Ceased
- 2011-11-04 AU AU2011323236A patent/AU2011323236B2/en active Active
- 2011-11-04 DK DK11838863.6T patent/DK2635297T3/da active
- 2011-11-04 MY MYPI2013001627A patent/MY165089A/en unknown
- 2011-11-04 CA CA2816575A patent/CA2816575C/en active Active
- 2011-11-04 KR KR1020137014351A patent/KR101948337B1/ko active Active
- 2011-11-04 ES ES11838863T patent/ES2721478T3/es active Active
- 2011-11-04 MX MX2016015430A patent/MX351220B/es unknown
-
2013
- 2013-05-05 IL IL226158A patent/IL226158B/en active IP Right Grant
- 2013-05-24 ZA ZA2013/03816A patent/ZA201303816B/en unknown
- 2013-06-05 CO CO13136450A patent/CO6720990A2/es unknown
-
2015
- 2015-08-25 US US14/834,769 patent/US10053500B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2600879T3 (es) | Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas | |
| ES2539812T3 (es) | Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos | |
| ES2691070T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
| CO6430475A2 (es) | Polipéptidos que tienen actividad de celulasa | |
| PE20170950A1 (es) | Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos | |
| ES2693321T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
| NZ609959A (en) | Modified factor ix polypeptides and uses thereof | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| PE20160507A1 (es) | Diferenciacion de celulas madre mesenquimales | |
| PE20141210A1 (es) | Mutantes de la polimerasa de hbv | |
| ES2723773T3 (es) | Luciferasas derivadas de Oplophorus, nuevos sustratos de celenterazina y procedimientos de uso | |
| AR083448A1 (es) | Polipeptidos con actividad quinasa | |
| ES2545895T3 (es) | Proteína de fusión anticancerígena | |
| CO6331367A2 (es) | Composiciones y metodos que comprenden variantes de celulasa con afinidad reducida para materiales no celulosicos | |
| NI201300143A (es) | Coagonista del receptor de glucagón/glp-1 | |
| ES2627117T3 (es) | Método basado en MGMT para obtener un rendimiento elevado de expresión de proteínas recombinantes | |
| PE20120501A1 (es) | L-asparaginasa tratada con peg | |
| MX351175B (es) | Detergente líquido para lavar vajillas estable al almacenamiento que contiene proteasa y amilasa. | |
| CR20120052A (es) | Polipéptidos del factor ix modificados y usos de los mismos | |
| AR089324A1 (es) | Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas | |
| AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
| MX2015011873A (es) | Dominios gla como agentes de direccionamiento. | |
| SG178797A1 (en) | Oligosaccharide chain added glp-1 peptide | |
| MX347600B (es) | Uso de una composicion que comprende un peptido antimicrobiano como un conservador de alimentos. | |
| AR102445A1 (es) | COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA |